MedTrace Logo

Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions.

NCT00764387 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 166

Last updated 2014-12-05

No results posted yet for this study

Summary

Study to compare of two contrast agents in imaging brain lesions.

Conditions

  • Neoplastic CNS Lesions

Interventions

DRUG

Gadovist® (Gadobutrol, BAY86-4875)

0,1 mmol/kg of body weight in the vein, single administration

DRUG

Dotarem

0,1 mmol/kg of body weight in the vein, single administration

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00764387 on ClinicalTrials.gov